이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Acupuncture for Depression: Sigma-1 Receptor-Related Brain Network Modulation

2026년 11월 12일 업데이트: Xinjing Yang, Shenzhen Hospital of Guangzhou University of Chinese Medicine

A Study on the Effects of Acupuncture in Treating Depression: Sigma-1 Receptor-Targeted pBFS for Individualized Brain Network Regulation and Prediction of Treatment Outcomes

This study will compare two types of acupuncture for adults with mild to moderate depression. One group will receive acupuncture. The other group will receive pivot acupuncture, a technique that uses needles at points on the head and neck. Participants with depression will be assigned to one of the two groups by chance. Both groups will attend three sessions a week for six weeks.

The researchers will compare how many people in each group have a substantial improvement in their depression symptoms by the end of treatment. They will also use brain scans and blood tests to examine whether symptom improvement is related to changes in how different parts of the brain work together and to changes in blood levels of a protein called the sigma-1 receptor.

연구 개요

상태

아직 모집하지 않음

상세 설명

In this parallel-group randomized trial, 72 adults with a mild to moderate depressive episode will be assigned in a 1:1 ratio to acupuncture or pivot acupuncture. The allocation sequence will be generated using SAS and concealed in sequentially numbered, opaque, sealed envelopes until treatment assignment.

Structural brain MRI, resting-state functional MRI, and peripheral blood sampling will be performed at baseline and at the end of the six-week treatment period. The personalized brain functional sectors (pBFS) method will be used to define 92 functional brain regions for each participant and estimate pairwise functional connectivity. The investigators will examine associations among changes in connectivity, peripheral sigma-1 receptor levels, and depressive symptoms. They will also explore whether changes in connectivity can estimate the magnitude of symptom improvement and compare models based on individualized and group-level brain maps.

연구 유형

중재적

등록 (추정된)

72

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Aged 18 to 60 years, inclusive.
  • Right-handed.
  • Diagnosed with a depressive episode according to ICD-10 code F32 and meeting DSM-5 criteria for a depressive episode.
  • Mild to moderate depressive symptoms, defined as a baseline score of at least 8 and less than 24 on the 17-item Hamilton Depression Rating Scale (HAMD-17).
  • No use of immunomodulators, antidepressants, or other medications that affect mood in the month before enrollment.
  • Willing and able to follow study procedures and provide written informed consent.

Exclusion Criteria:

  • Another psychiatric disorder, such as bipolar disorder or schizophrenia.
  • Autoimmune disease or acute infection.
  • Intellectual disability (IQ below 70) or autism spectrum disorder.
  • History of epilepsy or a brain lesion.
  • History of drug dependence.
  • A contraindication to acupuncture, electroacupuncture, or MRI, such as an infectious condition that precludes needling, a history of fainting with needling, claustrophobia, or an MRI-incompatible intracranial implant.
  • Suicide risk identified at screening.
  • Current participation in another clinical trial.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Acupuncture

Participants will receive acupuncture three times a week for six weeks, for a total of 18 sessions. Each session will last 30 minutes.

The primary points are Baihui (GV20) and Yintang. Baihui is needled transversely from anterior to posterior to a depth of 0.5-0.8 cun. Yintang is needled slowly in a superior direction to a depth of 0.5-0.8 cun and gently rotated to de qi. Additional points are Shenmen (HT7), Neiguan (PC6), Sanyinjiao (SP6), Zusanli (ST36), and Taichong (LR3). Sterile acupuncture needles measuring 0.30 × 25 mm or 0.30 × 40 mm are used. Qualified practitioners with at least five years of clinical experience administer treatment.

활성 비교기: Pivot Acupuncture

Participants will receive pivot acupuncture three times a week for six weeks, for a total of 18 sessions. Needles will be retained for 20 minutes at each session.

Needles are placed at Fengfu (GV16), Naohu (GV17), and bilateral Fengchi (GB20), Tianzhu (BL10), Wangu (GB12), Yifeng (TE17), Tianyou (TE16), and Anmian. With participants supine, the skin is disinfected with 75% alcohol. Sterile, single-use Huanqiu needles (Suzhou Huanqiu Acupuncture Medical Appliance Co., Ltd., China), 0.30 × 25 mm or 0.30 × 40 mm, are inserted rapidly. Fengchi is needled obliquely toward the tip of the nose to a depth of 10-23 mm. Fengfu is needled straight toward the mandible to a depth of 10-23 mm. Naohu is needled obliquely downward to a depth of 23 mm. Tianzhu, Wangu, Yifeng, Tianyou, and Anmian are needled perpendicularly to a depth of 30 mm. Needles are manipulated by lifting, thrusting, and rotating, then retained for 20 minutes. Treatment is administered without electrical stimulation.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants With a Clinical Response on the HAMD-17
기간: Baseline and Week 6 (end of treatment).

Clinical response is defined as a reduction of at least 50% from baseline in the total score on the 17-item Hamilton Depression Rating Scale (HAMD-17). The HAMD-17 is a clinician-rated measure of depressive symptom severity. Total scores range from 0 to 52, with higher scores indicating more severe symptoms.

Baseline and Week 6 (end of treatment).

2차 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants in Remission on the HAMD-17
기간: Week 6 (end of treatment).

Remission is defined as a total score below 8 on the 17-item Hamilton Depression Rating Scale (HAMD-17).

Week 6 (end of treatment).
Change From Baseline in HAMD-17 Total Score
기간: Baseline and Week 6 (end of treatment).

The Week 6 total score minus the baseline total score on the 17-item Hamilton Depression Rating Scale. Total scores range from 0 to 52, with higher scores indicating more severe symptoms. A negative change indicates improvement.

Baseline and Week 6 (end of treatment).
Change From Baseline in SF-12 Summary Score
기간: Baseline and Week 6 (end of treatment).

The 12-Item Short Form Health Survey (SF-12) is a self-reported measure of health status. Higher scores indicate better physical health. Change is calculated as the Week 6 score minus the baseline score.

Baseline and Week 6 (end of treatment).
Change From Baseline in BC-CCI-E Cognitive Complaints Score
기간: Baseline and Week 6 (end of treatment).

The British Columbia Cognitive Complaints Inventory-Expanded (BC-CCI-E) is a self-report measure of perceived cognitive difficulties. Higher cognitive complaints scores indicate more severe difficulties. Change is calculated as the Week 6 score minus the baseline score.

Baseline and Week 6 (end of treatment).
Suicide risk monitoring
기간: From enrollment through Week 10

Suicide risk will be assessed at baseline and weekly during the six-week treatment period using the Columbia-Suicide Severity Rating Scale (C-SSRS).

From enrollment through Week 10

기타 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants With at Least One Adverse Event
기간: From enrollment through Week 10

Adverse events will be recorded from enrollment through the final follow-up visit. The number and percentage of randomized participants with at least one adverse event will be summarized by treatment group.

From enrollment through Week 10

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2027년 12월 1일

연구 완료 (추정된)

2028년 1월 1일

연구 등록 날짜

최초 제출

2026년 11월 12일

QC 기준을 충족하는 최초 제출

2026년 11월 12일

처음 게시됨 (실제)

2026년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NO.JCYJ20250604191311016

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다